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With prolonged survival and aging of the HIV-infected
population in the era of antiretroviral therapy, biopsy series
have found a broad spectrum of HIV-related and co-morbid
kidney disease in these patients. Our study describes the
variety of renal pathology found in a prospective cohort of
antiretroviral-experienced patients (the Manhattan HIV Brain
Bank) who had consented to postmortem organ donation.
Nearly one-third of 89 kidney tissue donors had chronic
kidney disease, and evidence of some renal pathology was
found in 75. The most common diagnoses were
arterionephrosclerosis, HIV-associated nephropathy and
glomerulonephritis. Other diagnoses included pyelonephritis,
interstitial nephritis, diabetic nephropathy, fungal infection
and amyloidosis. Excluding 2 instances of acute tubular
necrosis, slightly over one-third of the cases would have been
predicted using current diagnostic criteria for chronic kidney
disease. Based on semi-quantitative analysis of stored
specimens, pre-mortem microalbuminuria testing could have
identified an additional 12 cases. Future studies are needed
to evaluate the cost-effectiveness of more sensitive methods
for defining chronic kidney disease, in order to identify
HIV-infected patients with early kidney disease who may
benefit from antiretroviral therapy and other interventions
known to delay disease progression and prevent
complications.
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Kidney disease was first described as a complication of the
acquired immunodeficiency syndrome (AIDS) in 1984, when
physicians in New York City described a unique form of
collapsing focal segmental glomerulosclerosis (FSGS) in
African-Americans and Haitian immigrants with AIDS.1
This kidney disease, now known as HIV-associated nephro-
pathy (HIVAN), occurred almost exclusively in blacks with
advanced AIDS and quickly became a leading cause of end-
stage renal disease (ESRD) among African-Americans.2
Although the incidence of new ESRD cases attributed to
HIVAN reached a plateau following the introduction of
combination antiretroviral therapy, the prevalence of HIV-
related ESRD continues to increase,2 at least in the United
States.3
With prolonged survival and aging of the HIV-infected
population in the United States and Western Europe, the
spectrum of kidney disease in patients with HIV also reflects
the growing burden of comorbid diabetes and hyperten-
sion.4,5 Kidney biopsy series have demonstrated an increasing
number of HIV-related and comorbid diagnoses in anti-
retroviral-treated patients,4,6 although patients who have
undergone clinically indicated kidney biopsy may not be
representative of all patients with HIV and kidney disease. A
recent biopsy study demonstrated early HIVAN in six South
African patients with microalbuminuria, who would not have
undergone kidney biopsy as part of standard clinical care.7 In
an earlier autopsy series, FSGS was identified in 3 of 40
Brazilian patients without overt glomerular disease.8 Recog-
nition of early, subclinical kidney disease may allow the
initiation of antiretroviral therapy and other interventions to
prevent or delay progression to ESRD.9
Autopsy series provide a unique window into the
spectrum of renal pathology in HIV-infected patients who
are unselected for the presence of overt kidney disease. The
majority of published autopsy series included patients who
died before the introduction of combination antiretroviral
therapy,10–19 or in resource-limited settings.20,21 Several
previous studies have focused on the specific diagnosis of
HIVAN,12,18 whereas others have described the involvement
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of multiple organ systems and have provided only superficial
descriptions of renal pathology.10,22 With few exceptions,17
autopsy series have also been limited by incomplete or absent
data on premortem kidney function. The Manhattan HIV
Brain Bank (MHBB) was established in 1998 to investigate
AIDS-related neuropathology and comorbid conditions in
the era of antiretroviral therapy.23 MHBB subjects are
selected for the presence of advanced HIV disease, and
consent to postmortem organ donation and to the prospec-
tive collection of clinical and laboratory data. This study
describes the prevalence of kidney pathology in a well-
characterized cohort of antiretroviral-experienced AIDS
patients, using clinical data and autopsy specimens from
the MHBB.
RESULTS
At the time of this analysis, the MHBB cohort included 244
active or deceased subjects, including 89 who had donated
kidney tissue at the time of rapid autopsy (Table 1). More
than one-third of MHBB participants were at least 50 years of
age, and nearly three-quarters were men. Consistent with the
epidemiology of the local HIV epidemic, half of the MHBB
subjects were African-American and nearly one-third were
Hispanic. Kidney tissue donors were similar to the overall
MHBB cohort with respect to demographic characteristics.
Clinical characteristics were reflective of the MHBB inclusion
criteria, which were designed to identify patients with
advanced HIV disease. Compared to the overall MHBB
cohort, deceased kidney tissue donors had more advanced
HIV disease. At the most recent study visit, nearly 75% of the
kidney tissue donors had a CD4 cell count o200 cells per
mm3, and HIV RNA was suppressed below 400 copies per ml
in only 30%. Nearly half of the kidney tissue donors were
coinfected with hepatitis C, and 13% with hepatitis B.
Although all MHBB subjects were antiretroviral treatment-
experienced, only 57% of kidney tissue donors were receiving
combination antiretroviral therapy at the study visit most
proximate to death. History of exposure to indinavir was
similar in kidney tissue donors and nondonors (43 versus
45%, P¼ 0.8). Previous or current use of tenofovir was less
common among kidney tissue donors (22 versus 49%,
Po0.0001), 45% of whom expired before its approval in late
2001.
At least one serum creatinine value was available for 87 of
the 89 kidney tissue donors, including 34 (39%) with an
estimated glomerular filtration rate (GFR) o60 ml/min per
1.73 m2. A total of 21 kidney tissue donors with a GFR
o60 ml/min per 1.73 m2 had one or more confirmatory
results separated by at least 3 months, establishing the
diagnosis of chronic kidney disease (CKD) according to
National Kidney Foundation (NKF) and Infectious Disease
Society of America guidelines.9,24 One subject without
confirmatory GFR estimates had a documented diagnosis
of advanced CKD, bringing the total number of kidney tissue
donors with stage 3 or higher CKD to 22 (24.7%). GFR
estimates were obtained a median of 75 days before death in
deceased subjects, most often during a routine study visit. In
all subjects whose final serum creatinine result was obtained
within 3 months of death, the diagnosis was confirmed using
earlier results.
At least one urinalysis result was available for 79 kidney
tissue donors. After excluding specimens with evidence of
urinary tract infection, 16 kidney tissue donors had at least
one urinary protein of 100 mg/100 ml or greater. A total of 10
of these subjects had one or more confirmatory results
separated by at least 3 months, indicating chronic kidney
damage.9,24 Four of these subjects also met GFR criteria for
the diagnosis of stage 3 or greater CKD, whereas six kidney
tissue donors with normal or mildly reduced GFR met
criteria for stages 1 and 2 CKD according to NKF and
Infectious Disease Society of America guidelines.9,24
Overall, 27 of 85 (31.8%) MHBB kidney tissue donors
with available data met current diagnostic criteria for CKD
based on the presence of proteinuria and/or an eGFR
Table 1 | Characteristics of the Manhattan HIV Brain Bank Cohort
All subjects (n=244) Kidney tissue donors (n=89) P-value*
Age (years) 47.4±8.4 46.5±8.4 0.2
Male sex 174 (71.3%) 66 (74.2%) 0.5
Black race 123 (50.4%) 43 (48.3%) 0.5
Hispanic ethnicity 79 (32%) 32 (36.0%) 0.4
Hepatitis B coinfection 26/191 (13.6%) 8/60 (13.3%) 0.9
Hepatitis C coinfection 98/237 (41.4%) 42/86 (48.8%) 0.08
CD4 cell count (cells per mm3) Median 150 (IQR 25–373) Median 70 (IQR 9–155) o0.0001
CD4 o200 cells per mm3 136 (55.7%) 69 (77.5%) o0.0001
Viral load o400 copies per ml 100/231 (43.3%) 24/80 (30.0%) 0.003
Serum albumin (g/100 ml) 3.37±0.96 2.82±0.96 o0.0001
Serum creatinine (mg/100 ml) Median 1.0 (IQR 0.8–1.4) Median 1.1 (IQR 0.7–2.1) 0.06
GFR (ml/min per 1.73 m2) Median 86 (IQR 55–126) Median 76 (IQR 32–128) 0.09
Chronic kidney diseasea 58/238 (24.4%) 27/85 (31.8%) 0.05
GFR o60 ml/min per 1.73 m2 44/238 (18.5) 21/85 (24.7%) 0.07
Proteinuria X100 mg/100 ml 26/218 (11.9%) 10/73 (13.7%) 0.6
GFR, glomerular filtration rate; IQR, interquartile range.
*P-value for the comparison of participants with and without available kidney tissue.
aChronic kidney disease: estimated glomerular filtration rate o60 ml/min per 1.73 m2 and/or proteinuria X100 mg/100 ml for at least 3 months.
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o60 ml/min/1.73 m2 for at least 3 months.9,24 The prevalence
of CKD among deceased kidney tissue donors was slightly
higher than that observed among active participants and
deceased participants without available kidney tissue (32
versus 20%, P¼ 0.05). In the overall cohort, clinical evidence
of CKD was associated with older age, black race (OR 1.92,
95% CI 1.04–3.54), and female gender (OR 2.34, 95% CI
1.26–4.36). In this cohort of antiretroviral-experienced
patients with advanced HIV/AIDS, disease-specific character-
istics such as CD4 cell count, HIV RNA, and hepatitis
coinfection were not associated with clinically evident CKD.
The spectrum of renal pathology is illustrated in Figures
1–3. Among the 89 subjects with kidney tissue available for
blinded review, 75 subjects (84%) had some evidence of renal
pathology. There were five subjects with mild isolated
arteriosclerosis and no other renal pathology, and only nine
subjects with no pathologic diagnosis (Table 2). Among the
75 participants with renal pathology, nonspecific and focal
changes including cortical scars, glomerulosclerosis, or
interstitial fibrosis were observed in 15. There were no
significant differences in demographics or HIV disease
characteristics between kidney tissue donors with and
without renal pathology. Clinically evident CKD was only
observed in the setting of renal pathology, with no cases of
CKD among participants with isolated arteriosclerosis or
with no pathologic diagnosis.
Arterionephrosclerosis was one of the most common
specific diagnoses, observed in 15 subjects. The diagnosis of
arterionephrosclerosis was only associated with a history of
hypertension in four participants (Table 3). Among the
participants without documented hypertension, two subjects
with arterionephrosclerosis were over the age of 50 years, and
two were engaged in active cocaine use as documented by
urine toxicology.
Findings consistent with HIVAN were observed in 12
African-Americans and 3 nonblack participants of Hispanic
ethnicity, all with advanced HIV disease (Figure 1). Among
the 15 subjects with HIVAN, 3 displayed collapsing
glomerulopathy and microcysts, 2 had collapsing glomerulo-
pathy without microcysts, and 8 had FSGS with microcysts
but lacking collapsing features. Two end-stage kidneys with
segmental glomerulosclerosis and focal tubular microcysts
were considered to represent advanced HIVAN. Only 4 of the
subjects with HIVAN were on antiretroviral therapy at the
time of death, and none had a suppressed plasma HIV viral
load. The CD4 cell count was below 200 cells per mm3 in 13
of the 15 subjects with HIVAN, and below 50 cells per mm3
in 7 subjects. Five of the subjects with HIVAN had already
reached ESRD at the time of death, and 5 others had GFR
o60 ml/min per 1.73 m2. Among the subjects with HIVAN
who had not reached ESRD, urinary protein of greater than
300 mg/100 ml was documented on at least one urinalysis in 7
of 9 subjects with available data. Four participants with mild
HIVAN had no premortem evidence of CKD.
Another common diagnosis was membranopro-
liferative pattern of glomerulonephritis (MPGN), which
was observed in 7 cases, including 3 associated with hepatitis
C coinfection (Figure 2). In one patient without hepatitis
C coinfection, the MPGN pattern may represent a chronic
glomerular thrombotic microangiopathy. A second patient
with membranoproliferative features had many glomerular
and arteriolar fibrin thrombi consistent with acute and
subacute thrombotic microangiopathy (Figure 2b). There was
also a single case of diffuse endocapillary proliferative and
exudative glomerulonephritis, suggestive of acute post-
infectious glomerulonephritis.
a b
c
Figure 1 | HIV-associated nephropathy. On blinded review of
kidney tissue obtained at the time of rapid autopsy, 15 of the
89 MHBB kidney tissue donors had findings consistent with
HIV-associated nephropathy (HIVAN). (a) Low power view
illustrates many glomerular microcysts and collapsed glomeruli
with dilatation of the urinary space (PAS, original magnification
 100). (b) A segment of the glomerular tuft is obliterated by
matrix material with capping of the overlying podocytes (PAS,
original magnification  600). (c) There is global tuft collapse with
podocyte vacuolation and dilatation of the urinary space (PAS,
original magnification  400).
a b
Figure 2 | Membranoproliferative glomerulonephritis. Another
common pathologic diagnosis in MHBB kidney tissue donors was
membranoproliferative glomerulonephritis (MPGN). Among the 7
cases of MPGN, 3 were associated with hepatitis C virus
coinfection. (a) There is global mesangial expansion by increased
mesangial cell number and matrix. The glomerular capillary
lumina are narrowed by extensive duplication of glomerular
basement membranes (PAS, original magnification  400). (b)
Membranoproliferative pattern with thrombotic microangiopathy.
There are many fibrin thrombi on a background of endothelial
swelling and double contouring of glomerular basement
membranes (PAS, original magnification  400).
430 Kidney International (2009) 75, 428–434
o r i g i n a l a r t i c l e CM Wyatt et al.: AIDS and kidney disease in the antiretroviral era
Other diagnoses included diabetic nephropathy
(Figure 3a), chronic pyelonephritis, and interstitial nephritis
(Figure 3b and c). One case of chronic interstitial nephritis
had numerous intratubular crystals consistent with indinavir
nephrotoxicity (Figure 3c). There were 3 cases of paren-
chymal mycoses, all occurring in patients with disseminated
fungal infection (Figure 3d and e), and a single case of
advanced renal amyloid was observed in a patient with
systemic amyloidosis (Figure 3f). Two subjects with isolated
premortem acute tubular necrosis died from overwhelming
infection, and one met criteria for CKD based on preexisting
hepatorenal syndrome in the setting of hepatitis B and C
coinfection. In addition to the two end-stage kidneys with
segmental glomerulosclerosis and focal tubular microcysts
suggestive of advanced HIVAN, there was a third case of
end-stage kidney of uncertain etiology.
The presence of renal pathology was poorly correlated
with premortem evidence of overt CKD. Excluding the two
cases of pre-terminal acute tubular necrosis, only 27 of the 73
cases (37%) with renal pathology would have been predicted
based on current diagnostic criteria for CKD (Table 2). In six
cases with renal pathology and no clinical evidence of CKD,
there were no urinalysis (n¼ 5) or serum creatinine (n¼ 1)
results available within the year before death. The most
common sub-clinical diagnoses were isolated arterionephro-
sclerosis or non-specific pathologic findings. In 5 cases of
chronic pyelonephritis and all 3 cases of parenchymal fungal
infection, there was no clinical evidence of CKD, with no
proteinuria or pyuria identified in 6 subjects with available
urine microscopy results. Among the 5 cases of interstitial
nephritis, one subject had overt CKD, one subject had pyuria,
and three subjects had no clinical evidence of overt renal
involvement, including one subject with no available
urinalysis results.
Although sub-clinical glomerular disease was less com-
mon, there were 4 cases of mild HIVAN, 4 cases of
glomerulonephritis, and 1 case of diabetic nephropathy that
would not have been predicted using the NKF definition of
CKD. On further review of these cases, two participants with
HIVAN and one with MPGN had 300 mg/100 ml of protein
on the urinalysis most proximate to death, but failed to meet
criteria for CKD because there were no prior confirmatory
results. A third participant with mild HIVAN and another
participant with MPGN had only 30 mg/100 ml of protein on
prior urinalyses, and the fourth subject with HIVAN had no
urinalysis results available within the year before death. One
subject with probable post-infectious glomerulonephritis had
a b
c d
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Figure 3 | Other renal pathology identified in MHBB kidney
tissue donors. (a) Diabetic glomerulosclerosis. There is global
mesangial sclerosis with segmental nodule formation. Glomerular
basement membranes and Bowman’s capsule are also thickened
(PAS, original magnification  400). (b) Chronic interstitial
nephritis. There is diffuse lymphocytic interstitial inflammation,
fibrosis, and tubulitis, with sparing of glomeruli (PAS, original
magnification  200). (c) Indinavir nephrotoxicity. The tubules
contain many intraluminal clear crystals with mononuclear
reaction (PAS, original magnification  400). (d) Cryptococcus.
Large rounded yeast forms dilate several glomerular capillaries.
(PAS, original magnification  400). (e) Candidiasis. Hyphal forms
infiltrate the interstitium and tubules (PAS, original magnification
 400). (f) Amyloidosis. The glomerular tuft is obliterated by pale
amorphous material that also occupies the renal interstitium (PAS,
original magnification  400).
Table 2 | Dominant renal pathology in 89 MHBB kidney tissue
donors
Pathologic diagnosis Total
Chronic kidney
diseasea
Arterionephrosclerosis 15 4
HIV-associated nephropathy 13 9
Glomerulonephritis 8 4
Membranoproliferative pattern (7)
Features of thrombotic
microangiopathy (2)
Probable post-infectious (1)
Chronic pyelonephritis 7 0
Acute or chronic interstitial nephritis 5 1
Indinavir crystals (1)
Parenchymal fungal infection 3 0
Cryptococcus (2)
Candida (1)
Diabetic nephropathy 3 2
End-stage kidney 4 4
Possible HIVAN (2)
Amyloidosis (1)
Unclear etiology (1)
Premortem acute tubular necrosis 2 1
Nonspecific changesb 15 2
Any renal pathology 75 27
Isolated arteriosclerosis/no renal pathology 14 0
HIVAN, HIV-associated nephropathy.
aPremortem evidence of chronic kidney disease.
bNonspecific changes: mild focal cortical scar, glomerulosclerosis, or interstitial
fibrosis.
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hematuria and pyuria, but no proteinuria, and the subject
with silent diabetic nephropathy had a single urinalysis with
100 mg/100 ml of protein more than 3 years earlier, with all
subsequent measurements below 30 mg/100 ml.
Stored urine specimens were available for semiquantitative
microalbuminuria testing in 30 additional participants with
renal pathology who did not meet clinical criteria for CKD,
including 5 subjects with sub-clinical glomerular disease.
Microalbuminuria testing was positive in the stored urine
specimen most proximate to death from 12 participants who
would not have been identified using standard diagnostic
criteria for CKD. Serial urine specimens were available for 7
of the 12 subjects, five of whom had persistent micro-
albuminuria. Among participants with subclinical glomerular
disease, microalbuminuria testing was positive in the speci-
men most proximate to death in 2 of the 5 subjects with
stored specimens, including one participant with diabetic
nephropathy and one with HIVAN. As mentioned previously,
three other subjects with HIVAN had at least one prior
urinalysis demonstrating proteinuria, but did not meet the
NKF definition for CKD. Microalbuminuria testing was
negative in stored specimens from three subjects with
glomerulonephritis.
DISCUSSION
In this well-characterized prospective cohort of antiretroviral
treatment-experienced patients with advanced HIV/AIDS, we
observed a high prevalence of both clinically evident CKD
and subclinical renal pathology. Among 89 kidney tissue
donors, postmortem histopathologic examination identified
46 cases of subclinical renal pathology that would not have
been predicted using current diagnostic criteria for CKD. The
prevalence of clinical CKD was increased among African-
Americans and women, consistent with previous studies
demonstrating an association between HIV-related kidney
disease and black race5,25,26 and female gender.25 In contrast
to some previous studies, HIV-related factors including HIV
viral load, CD4 cell count, and Hepatitis C coinfection were
not associated with clinical CKD or with the presence of renal
pathology in this cohort with advanced HIV/AIDS,5,27
although the histologic diagnosis of HIVAN was associated
with detectable HIV RNA.
Consistent with recent biopsy series in patients with HIV
infection, HIVAN and glomerulonephritis were two of the
most frequent diagnoses in the current study.4,6,7 The
spectrum of renal pathology also included a number of
diagnoses that are not commonly encountered in biopsy
series, in part because they are less likely to present with
clinical indications for kidney biopsy. Parenchymal infec-
tions, including chronic pyelonephritis and mycoses, have
been observed in previous autopsy series, particularly among
patients with advanced AIDS or in resource-limited set-
tings.13,17,20,21
The finding of subclinical glomerular disease in a small
number of subjects is also consistent with previous studies,
which have identified early FSGS in HIV-infected patients
without overt kidney disease.7,8 Retrospective analysis of
stored specimens from 5 subjects with subclinical glomerular
disease revealed microalbuminuria in 2 cases, including one
case of mild HIVAN. Overall, microalbuminuria was detected
in 12 subjects with renal pathology who did not meet
standard clinical criteria for CKD.
Although this study offers a rare opportunity to describe the
prevalence and spectrum of renal pathology in a cohort of
antiretroviral-experienced patients unselected for the presence
of overt kidney disease, a number of important limitations must
be acknowledged. Autopsy series are inherently limited by the
potential for postmortem tissue autolysis. The current study
focused on chronic glomerular, interstitial, and vascular
pathology, which are less sensitive to postmortem alterations.
In addition, the prospective design of the MHBB facilitates
rapid postmortem examination and harvesting of tissue, thereby
minimizing autolytic changes. The design of this study was also
limited by the lack of immunofluorescence and electron
Table 3 | Characteristics of MHBB kidney tissue donors with specific renal diagnoses
Arterionephrosclerosis (n=15) HIVAN (n=15)a Glomerulonephritis (n=8) Interstitial diseaseb (n=15)
Age 450 years 4 (27%) 5 (33%) 2 (25%) 5 (33%)
Male sex 11 (73%) 8 (53%) 8 (100%) 11 (73%)
Black race 7 (47%) 12 (80%)z 3 (38%) 4 (27%)
Hepatitis C coinfection 3/14 (21%) 8/14 (57%) 3/7 (43%) 7/14 (50%)
Current antiretroviral use 10 (67%) 4/14 (29%) 3/8 (38%) 7 (47%)
CD4 o200 cells per mm3 11 (73%) 13 (87%) 5 (63%) 13 (87%)
HIV RNA o400 copies per ml 3/14 (21%) 0/13 (0%)z 3/7 (43%) 4/13 (8%)
Persistent proteinuriac 1/12 (8%) 4/8 (50%)z 1/6 (17%) 1/13 (8%)
Hypertension 4/14 (29%) 3/14 (21%) 1 (13%) 1 (7%)
Diabetes mellitus 1/14 (7%) 0/14 (0%) 1 (13%) 0 (0%)
Active cocaine use 3/11 (27%) 6/11 (55%) 1/5 (20%) 5/11 (46%)
Active opiate use 3/11 (27%) 6/11 (55%) 2/5 (40%) 3/11 (27%)
HIVAN, HIV-associated nephropathy.
zP-value o0.01 for comparison with all other kidney tissue donors (Fisher’s exact).
aIncludes two cases of end-stage kidney suggestive of advanced HIVAN.
bInterstitial disease: interstitial nephritis, pyelonephritis, and parenchymal fungal infections.
cProteinuria X100 mg/100 ml for at least 3 months.
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microscopic analysis, which might have refined the diagnosis in
cases of glomerulonephritis. On the other hand, the evaluation
of over 100 glomeruli per case and the large sampling of
medullary parenchyma including pelvic urothelium had the
advantage of providing a broad sampling of both cortex and
medulla that is not attainable by needle biopsy. This was
particularly helpful to diagnose early forms of HIVAN affecting
a small percentage of glomeruli and relatively focal tubulointer-
stitial processes. In particular the presence of pelvic urothelium
made it possible to specifically diagnose chronic pyelonephritis,
as distinct from other forms of interstitial nephritis.
Autopsy series are also susceptible to inherent selection
bias, and MHBB subjects who have succumbed to AIDS may
not be representative of all persons living with HIV in the era
of antiretroviral therapy. MHBB subjects were selected for the
presence of advanced HIV disease at the time of enrollment,
and the results of this study may not be generalizable to
patients with well-controlled HIV infection. In fact, the
prevalence of clinically evident CKD observed in MHBB
kidney tissue donors was higher than that recently reported
in other urban HIV populations with a broader range of HIV
disease severity.5,25 Clinical evidence of CKD was more
common among deceased MHBB participants, consistent
with the observed association between CKD and increased
mortality in the general population28,29 and in patients with
HIV.30 Half of the subjects with subclinical renal pathology
had nonspecific changes or renal parenchymal infection on
postmortem examination. Although these diagnoses may not
cause classic CKD, it is unknown whether this type of
underlying kidney injury could predispose patients with
HIV/AIDS to acute kidney injury in the setting of recurrent
sepsis or exposure to nephrotoxic medications. Microalbu-
minuria testing was performed on the stored urine specimen
most proximate to death. Although a single microalbumi-
nuria measurement is inadequate for screening purposes,31
the results are likely to be more reproducible in the setting of
underlying renal pathology, and 5 of 7 subjects with serial
urine specimens available for analysis had persistent micro-
albuminuria.
This study demonstrates a high prevalence of clinical CKD
and renal pathology in a cohort of antiretroviral-experienced
patients with advanced HIV/AIDS. More than half of the
observed renal pathology would not have been predicted
based on current clinical criteria for CKD, although
microalbuminuria screening may have identified additional
cases. Recognition of subclinical kidney disease may allow
targeted interventions to prevent or delay the progression of
kidney disease and to avoid complications such as medica-
tion nephrotoxicity and acute kidney injury. Future studies
should evaluate the cost-effectiveness of microalbuminuria
screening and the use of more sensitive criteria or more
frequent screening for CKD to identify HIV-infected
patients with early kidney disease, who may benefit
from the initiation of antiretroviral therapy or other
interventions such as ACE inhibitors or angiotensin receptor
blockers.9
MATERIALS AND METHODS
The MHBB was established in 1998 to investigate AIDS-related
neuropathology, neurocognitive deficits, and comorbid conditions
in the era of antiretroviral therapy. The study design and eligibility
criteria have been described previously.23 Briefly, HIV-positive
patients are eligible for enrollment in the MHBB if they have
advanced HIV disease, as indicated by a prespecified AIDS-defining
condition or a CD4 cell count persistently p50 cells per mm3, or if
they are at risk for imminent mortality in the clinical judgment of
the treating physician. Following enrollment, participants who
respond to effective antiretroviral therapy with improvement in
these clinical parameters may remain in the MHBB cohort. MHBB
subjects consent to postmortem organ donation, and to the
collection of clinical and laboratory data through patient interview
and medical record review. All subjects provide written informed
consent, and the MHBB has been approved by the Institutional
Review Boards at all enrolling sites. This study was approved by the
Program for the Protection of Human Subjects of the Mount Sinai
School of Medicine.
Basic demographic, clinical, and laboratory data were analyzed
for all active and deceased subjects to describe the prevalence of
clinically evident kidney disease in the cohort. The most recent
serum creatinine values for each subject were used to estimate GFR
using the four-variable Modification of Diet in Renal Disease
equation.9 Proteinuria was defined as the presence of 100 mg/100 ml
or greater protein on quantitative urinalysis, excluding specimens
with evidence of active infection (leukocyte count 410 cells per
high power field). CKD was defined according to the NKF
and Infectious Disease Society of America guidelines as a GFR
o60 ml/min per 1.73 m2 and/or the presence of proteinuria,
confirmed on two or more measurements separated by at least 3
months.9,24 Hepatitis B coinfection was defined by surface
antigenemia or the detection of viral DNA. Hepatitis C coinfection
was defined by the detection of hepatitis C antibody or viral RNA; in
cases where both hepatitis C antibody and RNA results were
available, RNA results were used to determine hepatitis C status.
Because the sensitivity of HIV-1 RNA testing has evolved during the
study period, HIV viral load was considered suppressed for all values
below 400 copies per ml. For kidney tissue donors, additional data
on comorbid conditions (documented diagnosis of diabetes mellitus
or hypertension based on the clinical judgment of the treating
physician) and cause of death were abstracted from the study chart,
and evidence of active cocaine or opiate use was determined by
urine toxicology results.
Pathologic analysis was limited to light microscopy. Hematoxylin
and eosin and Periodic Acid-Schiff (PAS)-stained slides were
prepared from a large wedge of cortex and medulla that had been
fixed promptly in formalin at the time of autopsy. Sections (3mm)
were reviewed by a single-blinded pathologist (VD’A), focusing on
glomerular, tubulointerstitial, and vascular pathology, whereas
discounting autolytic changes. On average, over 100 glomeruli were
sampled per section. HIVAN was defined as FSGS with either focal
collapsing features or tubular microcysts. To fulfill the definition of
collapse, glomeruli had to demonstrate wrinkling and collapse of the
glomerular basement membranes with overlying podocyte hyper-
trophy and hyperplasia. Arteriosclerosis was defined as narrowing of
intrarenal arteries of any caliber by intimal sclerosis. Mild
arteriosclerosis was graded as intimal thickening involving p25%
of the luminal diameter. Arterionephrosclerosis consisted of
arteriosclerosis accompanied by focal global glomerulosclerosis
and focal tubular atrophy and interstitial fibrosis in a patchy,
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vascular distribution, often producing subcapsular scars. Chronic
pyelonephritis was defined as chronic pyelitis with interstitial
nephritis affecting cortex and medulla. The membranoproliferative
pattern was defined as extensive mesangial interposition and
duplication of glomerular basement membranes. End-stage kidney
was reserved for those cases with 490% global glomerulosclerosis
and tubular atrophy and interstitial fibrosis affecting 490% of the
renal parenchyma.
Stored urine specimens from subjects with subclinical renal
pathology were analyzed for the presence of microalbuminuria by
semiquantitative dipstick (Bayer Diagnostics, Elkhart, Indiana).
Persistent microalbuminuria was defined as a positive result in at
least two of three consecutive specimens. Comparisons between
subjects with and without available tissue and those with and
without evidence of CKD or renal pathology were performed by w2
or Fisher’s exact test for dichotomous variables and by t-tests or
Wilcoxon’s rank-sum for continuous variables.
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